Publikationen

2022

Blazejak C, Stranzenbach R, Gosman J, Gambichler T, Wehkamp U, Stendel S, Klemke CD, Wobser M, Olk J, Nicolay JP, Weyermann M, Stadler R, Assaf C.Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network. Dermatology. 2022; 238(3):498-506.

Albrecht JD, Nicolay JP. Current therapeutic options in Mycosis fungoides and Sézary syndrome. Hautarzt. 2022; 73(1):75-85.

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, Eich HT, Elsayad K, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Loquai C, Meiss F, Mitteldorf C, Wehkamp U, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stranzenbach R, Moritz R, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021. J Dtsch Dermatol Ges. 2022; 20(4):537-555.

Kempf W, Petrella T, Willemze R, Jansen P, Berti E, Santucci M, Geissinger E, Cerroni L, Maubec E, Battistella M, Goodlad J, Guenova E, Lappalainen K, Ranki A, Craig P, Calonje E, Martin B, Whittaker S, Oschlies I, Wehkamp U, Nicolay JP, Wobser M, Scarisbruck J, Pimpinelli N, Stadler R, Kerl French K, Quaglino P, Lin J, Chen L, Beer M, Emanuel P, Dalle S, Robson A. Clinical, histopathological and prognostic features of primary cutaneous acral CD8⁺ T-cell lymphoma and other dermal CD8⁺ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop. Br J Dermatol. 2022; 186(5):887-897.

Assaf C, Booken N, Dippel E, Guenova E, Jonak C, Klemke CD, Nicolay JP, Schlaak M, Wobser M, Trautinger F. The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region). J Dtsch Dermatol Ges. 2022; 20(5):579-586.

Albrecht JD, Ninosu N, Barry D, Albrecht T, Schaarschmidt ML, Goerdt S, Nicolay JP. Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects. Acta Derm Venereol. 2022; 102:adv00722.

2021

Vermeer MH, Nicolay JP, Scarisbrick JJ, Zinzani PL. The importance of assessing blood tumour burden in cutaneous T-cell lymphoma. Br J Dermatol. 2021; 185(1):19-25.

Wehkamp U, Mitteldorf C, Stendel S, Stranzenbach R, Nicolay JP, Wobser M, Weichenthal M, Schneiderbauer R, Klemke CD, Hillen U, Kempf W, Assaf C. Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network. Br J Dermatol. 2021; 185(1):228-230.

Nicolay JP, Albrecht JD, Alberti-Violetti S, Berti E. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver. Eur J Immunol. 2021; 51(7):1660-1671.

Cowan RA, Scarisbrick JJ, Zinzani PL, Nicolay JP, Sokol L, Pinter-Brown L, Quaglino P, Iversen L, Dummer R, Musiek A, Foss F, Ito T, Rosen JP, Medley MC. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. J Eur Acad Dermatol Venereol. 2021;35(11):2225-2238.

2020

Brüggen MC, Valencak J, Stranzenbach R, Li N, Stadler R, Jonak C, Bauer W, Porkert S, Blaschke A, Meiss F, Nicolay JP, Wehkamp U, Schlaak M, Nguyen VA, Romani N, Cozzio A, Gayathri N, Dimitriou F, French LE, Dummer R, Guenova E. Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020; 34(7):1489-1495.

2019

Hambsch J, Büttner S, Heck M, Nicolay JP, Felcht M, Booken N, Klemke CD.Single-center retrospective analysis of extracorporal photopheresis in clinical practice: Peripheral venous compared to central venous access. Hautarzt. 2019; 70(3):193-203.

Felcht M, Klemke CD, Nicolay JP, Weiss C, Assaf C, Wobser M, Schlaak M, Hillen U, Moritz R, Tantcheva-Poor I, Nashan D, Beyer M, Dippel E, Müller CSL, Sachse MM, Meiss F, Géraud C, Marx A, Goerdt S, Geissinger E, Kempf W. Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences. J Dtsch Dermatol Ges. 2019; 17(3):275-285.

Froehlich TC, Müller-Decker K, Braun JD, Albrecht T, Schroeder A, Gülow K, Goerdt S, Krammer PH, Nicolay JP. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma. Blood. 2019; 134(5):445-455.

2018

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86). J Dtsch Dermatol Ges. 2018; 16(1):112-122.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(9):1192-1204.

2017

Schroeder A, Warnken U, Röth D, Klika KD, Vobis D, Barnert A, Bujupi F, Oberacker T, Schnölzer M, Nicolay JP, Krammer PH, Gülow K. Targeting Thioredoxin-1 by dimethyl fumarate induces ripoptosome-mediated cell death.  Sci Rep. 2017; 7:43168.

Benecke J, Géraud C, Nicolay JP. Cutaneous Gamma-delta T-cell Lymphoma with an Initially Indolent Course Mimicking Lupus Panniculitis.  Acta Derm Venereol. 2017; 97(5):665-666.

Kießling MK, Nicolay JP, Schlör T, Klemke CD, Süss D, Krammer PH, Gülow K. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.  Oncotarget. 2017; 8(28):45687-45697.

Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86). J Dtsch Dermatol Ges. 2017;15(12):1266-1273.

2016

Nicolay JP, Wobser M. Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy. J Dtsch Dermatol Ges. 2016; 14: 1207-1224.

Nicolay JP, Schneider S, Gaiser T, Felcht M, Klemke CD. Differential expression of cancer stem cell markers in cutaneous and systemic lymphoma. Exp Dermatol. 2016; 25: 561-3.

Nicolay JP, Muller-Decker K, Schroeder A, Brechmann M, Mobs M, Geraud C, Assaf C, Goerdt S, Krammer PH, Gulow K. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-kappaB. Blood. 2016; 128: 805-15.

Nicolay JP, Felcht M, Schledzewski K, Goerdt S, Geraud C. Sezary syndrome: old enigmas, new targets. J Dtsch Dermatol Ges. 2016; 14: 256-64.

2015

Teichert M, Stumpf C, Booken N, Wobser M, Nashan D, Hallermann C, Mogler C, Muller CS, Becker JC, Moritz RK, Andrulis M, Nicolay JP, Goerdt S, Thomas M, Klemke CD, Augustin HG, Felcht M. Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis. Exp Dermatol. 2015; 24: 424-9.

Ruggiero E*, Nicolay JP*, Fronza R, Arens A, Paruzynski A, Nowrouzi A, Urenden G, Lulay C, Schneider S, Goerdt S, Glimm H, Krammer PH, Schmidt M, von Kalle C. High-resolution analysis of the human T-cell receptor repertoire. Nat Commun. 2015; 6: 8081. *contributed equally

Klemke CD, Booken N, Weiss C, Nicolay JP, Goerdt S, Felcht M, Geraud C, Kempf W, Assaf C, Ortonne N, Battistella M, Bagot M, Knobler R, Quaglino P, Arheiliger B, Santucci M, Jansen P, Vermeer MH, Willemze R. Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol. 2015; 173: 93-105.

2014

Nicolay JP, Klemke CD. [Management of cutaneous lymphomas]. Hautarzt. 2014; 65: 607-13.

2013

Booken N, Nicolay JP, Weiß C, Goerdt S, Klemke CD. Cutaneous tumour cell load correlates with survival in patients with Sézary syndrome. J Dtsch Dermatol Ges. 2013 Jan;11(1):67-79.

2012

Felcht M, Heck M, Weiss C, Becker JC, Dippel E, Müller CS, Nashan D, Sachse MM, Nicolay JP, Booken N, Goerdt S, Klemke CD. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumor cells. Br J Dermatol. 2012 Aug;167(2):348-58..

Booken N, Goerdt S, Klemke CD. Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry. J Dtsch Dermatol Ges. 2012 May;10(5):331-9.

Brechmann M, Mock T, Nickles D, Kiessling M, Weit N, Breuer R, Muller W, Wabnitz G, Frey F, Nicolay JP, Booken N, Samstag Y, Klemke CD, Herling M, Boutros M, Krammer PH, Arnold R. A PP4 holoenzyme balances physiological and oncogenic nuclear factor-kappa B signaling in T lymphocytes. Immunity. 2012; 37: 697-708.

2011

Felcht M, Booken N, Stroebel P, Goerdt S, Klemke CD. The value of molecular diagnosis and molecular staging in primary cutaneous B-cell lymphomas. J Am Acad Dermatol 2011 Jan;64(1):135-43.

Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011 Mar;164(3):665-7.

Klemke CD. Systemic treatment of cutaneous lymphomas. Hautarzt. 2011 Jun;62(6):436-43.

2010

Booken N, Weiß C, Utikal J, Felcht M, Goerdt S, Klemke CD. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome. J Dtsch Dermatol Ges. 2010 Jun;8(6):428-38.

2009

Kiessling M, Klemke CD, Kamiński M, Galani I, Krammer PH, Gülow K. Inhibition of NF-κB induces Iron- and ROS-dependent Cell Death by downregulation of Ferritin Heavy Chain in T cell lymphoma. Cancer Res. 2009;69:2365-74.

Klemke CD, Brenner D, Weiß EM, Schmidt M, Leverkus M, Gülow K, Krammer PH. The lack of T cell receptor induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T cell lymphoma cells from Activation-Induced Cell Death. Cancer Res. 2009;69:4175-4183.

Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E, Klemke CD. FOXP3+CD25- tumor cells with regulatory function in Sézary Syndrome. J Invest Dermatol 2009;129:2875-85.

2008

Booken N, Gratchev A, Utikal J, Weiß C, Yu X, Qadoumi M, Schmuth M, Sepp N, Nashan D, Rass K, Tüting T, Assaf C, Dippel E, Stadler R, Klemke CD, Goerdt S. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia. 2008;22:393-9.

Stadler R, Assaf C, Klemke CD, Nashan D, Weichenthal M, Dummer R, Sterry W. Kurzleitlinie – Kutane Lymphome. J Dtsch Dermatol Ges. 2008;6 (Supplement 1):S29-S35.

Klemke CD, Brade J, Weckesser S, Sachse MM, Booken N, Neumaier M, Goerdt S, Nebe TC. Diagnosis and follow-up of blood involvement in patients with Sézary syndrome. Br J Dermatol. 2008;159(4):871-80.

Klemke CD. Mykosis fungoides. CME Dermatologie 2008;3:106-122.

2006

Utikal J, Poenitz N, Gratchev A, Klemke CD, Nashan D, Tüting T, Goerdt S. Additional Her 2/neu gene copies in patients with Sézary syndrome. Leuk Res. 2006 30(6):755-60.

Klemke CD, Poenitz N, Dippel E, Hummel M, Stein H, Goerdt S. T-cell clonality of undetermined significance. Arch Dermatol 2006;142:393-394.

Klemke CD, Fritzsching B, Franz B, Kleinmann E, Oberle N, Poenitz N, Sykora J, Banham AH, Roncador G, Goerdt S, Krammer PH, Suri-Payer E. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary Syndrome from other cutaneous T cell lymphomas. Leukemia 2006;20:1123-9.

Klemke CD, Goerdt S, Schrama D, Becker JC. Kutanes T-Zell Lymphom: Von der Molekularbiologie zur zielgerichteten Therapie. J Dtsch Dermatol Ges. 2006;4:395-405.

2005

Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL-Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005;153:118-24.

Poenitz N, Simon-Ackermann J, A. Gratchev A, Qadoumi M, Klemke CD, Stadler R, Kremer A, Radenhausen M, Henke U, Assaf C, Utikal J, Goerdt S, Dippel E. Overexpression of c-myb in leukemic and non-leukemic variants of cutaneous T-cell lymphoma. Dermatology 2005;211:84-92.

2003

Poenitz N, Dippel E, Klemke CD, Qadoumi M, Goerdt S. Jessner’s lymphocytic infiltration of the skin: a CD8+ polyclonal reactive skin condition. Dermatology. 2003;207:276-84.

2002

Klemke CD, Dippel E, Dembinski A, Ponitz N, Assaf C, Hummel M, Stein H, Goerdt S. Clonal T cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in the skin and blood of patients with parapsoriasis and early-stage mycosis fungoides. J Pathol. 2002;197:348-54.

2001

Dippel E, Klemke CD, Hummel M, Stein H, Goerdt S. T-cell clonality of undetermined significance. Blood 2001;98:247-8.